GlassScriptPhysician profile
Cami Lee E Mcchesney
NPI 1467977116
$1,873.52
in general payments reported to CMS, 2019-2025
19 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $335 · 2023: $448 · 2024: $546 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $432.64 | 2021-2025 | Farxiga, Airsupra |
| Daiichi Sankyo INC. | $197.33 | 2024 | Injectafer |
| Amgen INC. | $123.88 | 2021-2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $122.87 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $118.96 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $117.36 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $108.15 | 2023-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $106.84 | 2022 | |
| Glaxosmithkline, LLC. | $88.35 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $73.80 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $71.29 | 2021-2023 | Mounjaro |
| Biohaven Pharmaceuticals, INC. | $69.51 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.67 | 2022-2025 | |
| Abbvie INC. | $57.50 | 2022-2023 | |
| Shield Therapeutics INC | $35.84 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $26.75 | 2021-2022 | |
| Dynavax Technologies Corporation | $23.24 | 2024 | Heplisav-B |
| Depuy Synthes Sales INC. | $20.17 | 2024 | Monovisc, Orthovisc |
| E.R. Squibb & Sons, L.L.C. | $13.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cami Lee Mcchesney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.